A kind of compound preparation of aspirin and rivaroxaban and preparation method thereof

A technology of rivaroxaban and aspirin is applied in the field of compound preparations of aspirin and rivaroxaban and their preparation, which can solve the problems such as no cases of successful research and development, and achieve the purpose of preventing the recurrence of myocardial infarction, reducing the risk of missed doses, The effect of reducing the risk of missed doses

Active Publication Date: 2022-01-07
LEPU PHARMACEUTICAL CO LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In view of the characteristics of rivaroxaban, it is a great technical challenge to develop a sustained-release formulation to be taken once a day, and no successful case has been seen so far

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of compound preparation of aspirin and rivaroxaban and preparation method thereof
  • A kind of compound preparation of aspirin and rivaroxaban and preparation method thereof
  • A kind of compound preparation of aspirin and rivaroxaban and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0076] Example 1: Preparation of Rivaroxaban Sustained-release Tablets (I)

[0077] Table 1 Composition of Rivaroxaban Sustained-release Tablets (I)

[0078]

[0079] Preparation Process:

[0080] Granulation: add the other materials of the plain tablet except magnesium stearate into the wet granulator, the speed of the stirring paddle is 300rpm, the cutting knife is 500rpm, and mix for 5min; Finish adding in about 7 minutes; the speed of the stirring blade is 250rpm, the cutter is 1200rpm, and the granulation is 2min; the material is discharged, the screen of the granulator is 3×3mm, the speed is 400rpm, and the granules are wet granulated; the wet granules are added to the fluidized bed, and the air is 60°C , air volume 30Hz, drying, when the temperature of the material reaches 40°C, take a sample to measure the moisture, stop heating when the moisture is lower than 2.0%, cool and discharge; the screen diameter of the granulator is 1.0mm, the speed is 400rpm, dry granula...

Embodiment 2

[0084] Example 2: Preparation of Rivaroxaban Sustained-release Tablets (II)

[0085] Table 2 Composition of Rivaroxaban Sustained-release Tablets (Ⅱ)

[0086] Name of raw material model Unit prescription (mg / tablet) Rivaroxaban D90<15um

5 Hypromellose 2280 K100M 6 Hypromellose 2910 E50 24 microcrystalline cellulose SH-101 25 lactose monohydrate 200 mesh 16 Hypromellose EXF 3.2 Magnesium stearate / 0.8 Hypromellose 2910 E5 3.2 polyethylene glycol PEG6000 0.8

[0087] Preparation Process:

[0088] Granulation: add the other materials of the plain tablet except magnesium stearate into the wet granulator, the speed of the stirring paddle is 300rpm, the cutting knife is 500rpm, and mix for 5min; Finish adding in about 7 minutes; the speed of the stirring blade is 250rpm, the cutter is 1200rpm, and the granulation is 2min; the material is discharged, the screen of the granulator is 3×3mm, the s...

Embodiment 3

[0092] Example 3: Preparation of Rivaroxaban Sustained-release Tablets (Ⅲ)

[0093] Table 3 Composition of Rivaroxaban Sustained-release Tablets (Ⅲ)

[0094] Name of raw material model Unit prescription (mg / tablet) Rivaroxaban D90<15um

1.25 Hypromellose 2280 K100M 2.5 Hypromellose 2910 E50 6 microcrystalline cellulose SH-101 4.1 lactose monohydrate 200 mesh 5.25 Hypromellose EXF 0.8 Magnesium stearate / 0.1 Hypromellose 2910 E5 1.6 polyethylene glycol PEG6000 0.4

[0095] Preparation Process:

[0096] Granulation: add the other materials of the plain tablet except magnesium stearate into the wet granulator, the speed of the stirring paddle is 300rpm, the cutting knife is 500rpm, and mix for 5min; Finish adding in about 7 minutes; the speed of the stirring blade is 250rpm, the cutter is 1200rpm, and the granulation is 2min; the material is discharged, the screen of the granulator is 3×3mm,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
hardnessaaaaaaaaaa
hardnessaaaaaaaaaa
Login to view more

Abstract

The invention discloses a compound pharmaceutical preparation of aspirin and rivaroxaban and a preparation method thereof. The compound preparation is formed by filling capsules with aspirin microtablets and rivaroxaban microtablets. Among them, aspirin is enteric-coated release, rivaroxaban is sustained-release, and is used for the treatment of related diseases such as thrombolysis and prevention of thrombosis. Each capsule is filled with 1-4 tablets, the specification of the rivaroxaban sustained-release microtablets is 1.25-20 mg / tablet, and each capsule is filled with 1-8 tablets. The composite solid preparation of the present invention fills different medicines and different types of microtablets in the same capsule to make a compound preparation, which is convenient for patients to take and reduces the risk of missed doses. Moreover, the capsule is easy to open, and the capsule filled with microchips has a more flexible way of taking medicine.

Description

technical field [0001] The invention belongs to the technical field of medicines, and in particular relates to a compound preparation of aspirin and rivaroxaban and a preparation method thereof. Background technique [0002] Aspirin is a commonly used antithrombotic drug on the market. Its antithrombotic mechanism is: irreversibly inhibiting the synthesis of cyclooxygenase, reducing the production of prostaglandins and inhibiting the production of platelet thromboxane A2, thereby inhibiting platelet adhesion and aggregation, affecting Formation of thrombus. [0003] Rivaroxaban is an oral anticoagulant that directly inhibits factor Xa with high selectivity. By directly inhibiting factor Xa, the intrinsic and extrinsic pathways of the coagulation cascade can be interrupted, thrombin generation and thrombus formation can be inhibited. Rivaroxaban was developed by Bayer Pharmaceuticals, Germany, and was approved for marketing by the European Union on September 30, 2008. It w...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/616A61K9/62A61K9/58A61P7/02A61P9/10A61P9/00A61P9/06A61K31/5377A61K9/36A61K9/32
CPCA61K31/616A61K31/5377A61K9/5084A61P7/02A61P9/10A61P9/00A61P9/06A61K9/2846A61K9/2866A61K2300/00
Inventor 付晓宁骆献丽朱建中刘文省
Owner LEPU PHARMACEUTICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap